异基因造血干细胞移植前后应用地西他滨治疗骨髓增生异常综合征转化的急性髓系白血病——1例治疗经验及文献复习  

The treatment of decitabine in acute myeloid leukemia transformed by myelodysplastic syndrome before and after allogeneic hematopoietic stem cell transplantation:a case report and literature review

作　　者：许国发[1] 陈婷 蔺诗佳 刘焕凤 邓天霞 高蕾 刘耀 张诚 高力 张曦 孔佩艳 

机构地区：[1]重庆市涪陵中心医院血液科,重庆400800 [2]陆军军医大学第二附属医院新桥医院血液科

出　　处：《临床血液学杂志》2018年第1期52-56,共5页Journal of Clinical Hematology

摘　　要：骨髓增生异常综合征（myelodysplastic syndrome,MDS）转化的急性髓系白血病（acute myeloid leukemia,AML）完全缓解（CR）率低,约为36%,生存期短,预后差[1]。有研究报道19.2%32.0%的AML患者存在FLT3-ITD突变,其中AML-M3患者的阳性率最高,Acute myeloid leukemia（AML）transformed by myelodysplastic syndrome（MDS）has low complete remission,high risk of relapse,short survival time and poor prognosis.If the patients also with FLT3-ITD positive,the outcome will be worse,and the possibility of survival is very low,even after allogeneic hematopoietic stem cell transplantation（Allo-HSCT）.In this paper a 44 year old female patient with FLT3-ITD＋AML-M5,transformed by MDS treated in our department were reported.The patient received chemotherapy with decitabine before and unrelated donor Allo-HSCT,and maintenance therapy of small dose of decitabine after HSCT.The early relapse after transplantation was successfully controlled,and the life of the patient had been over 2 years.

关 键 词：FLT3-ITD阳性 急性髓系白血病 骨髓增生异常综合征 地西他滨 异基因造血干细胞移植 无关供者 

分 类 号：R733.7[医药卫生—肿瘤]